With Increased Clinical Success,Vomaris Expands Executive Team

With Increased Clinical Success,Vomaris Expands Executive Team

CHANDLER, Ariz., Sept. 16, 2013 -- Vomaris® is pleased to announce Cynthia Ann Fleck, RN, BSN, MBA, has joined the company in the role of Vice President Clinical Sales and Marketing.

With more than 10 years of experience in the professional medical, surgical and biotech sales and clinical marketing arenas, and over 15 years in the clinical field, Fleck will be focused on growing the company's share of market in its professional healthcare division. The company's other divisions are ProcelleraElite OTC and ProcelleraAnimal Care.

"Cynthia is an accomplished clinician, author, educator, speaker and proven leader who brings to Vomaris invaluable experience in the sales and clinical realm," said Vomaris® CEO Michael Nagel.

"Her solid track record and strong blend of sales and clinical knowledge will no doubt make her an incredible asset in helping to drive the company's growth initiatives. We are delighted to have Cynthia play an integral part of our team and are confident in what she will bring to accelerate Procellera's professional healthcare division."

Prior to joining Vomaris Innovations, Fleck served as Vice President, Clinical Marketing at Medline Industries where she oversaw Clinical Marketing for Advanced Skin and Wound Care. Her previous roles include Past President and Chairman of the Board of the American Board of Wound Management (ABWM), Past Director of the Association for the Advancement of Wound Care (AAWC), Chair of PRESENT WOC, Co-Chair of the Desert Foot Conference, Medical Advisory Board Member of the American Professional Wound Care Association, PRESENT Diabetes and Mount Sinai School of Medicine Advisory Board Member, Board Member of the American College of Clinical Wound Specialists and President of Cynthia Fleck & Associates, LLC.

About Vomaris®
Vomaris Innovations, Inc., based in Chandler, Arizona, is a leading edge regenerative medical device company specializing in microcurrent field generating technologies for the wound care market. Its product, Procellera®, is the world's first self-contained antimicrobial wound dressing with a matrix of microcell batteries at its surface. Procellera® is a unique device due to its inherent design with microcurrent technology. Procellera® is indicated for over-the-counter (OTC) and professional (Rx) uses. Randomized clinical trials are in process looking at other possible wound healing benefits for the use of Procellera®.

For more information, visit http://www.vomaris.com or call 480.921.4948.

SOURCE Vomaris Innovations, Inc.

Suggested Articles

IBM and Pfizer developed an artificial intelligence model that could eventually predict if a person will develop Alzheimer’s using a language test.

After teaming up with other Big Pharmas to bolster antibiotics research, Pfizer is adding a new antibiotic prospect to its pipeline.

The oral direct-acting antiviral is set to enter a phase 3 trial in non-hospitalized patients early next year.